Press Releases Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
11.02 ^USD	-1.34%		+9.65%	-51.45%

May. 15	Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference	May. 29	GL
Cabaletta Bio : Corporate Presentation	May. 15	PU
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update	May. 15	GL
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	May. 13	GL
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	May. 13	AQ
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 21	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	Mar. 20	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis	Mar. 20	AQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in March	Feb. 27	GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis	Feb. 01	GL
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	Jan. 08	GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	Jan. 08	AQ
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	GL
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference	Nov. 28	GL
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 09	GL
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform	Nov. 06	BU
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis	Nov. 06	GL
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November	23-10-30	GL
Cabaletta Bio : Corporate Presentation	23-10-02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Press Releases

Filters